Magnosco

Curated by Signal

Developer of device for the diagnosis of skin cancer

Overview

Magnosa develops a device for the diagnosis of cancer. develops patented devices for the early detection of early malignant melanoma, the so-called dermatofluoroscopy. The diagnosis is based on infrared laser technology and artificial intelligence.

Key facts

Founded: 2013
Headquarters: Berlin, Germany
Stage: Sign up to view
Industry: Life Sciences Technology

Business model

2 products and services: Sign up to view

Contact

Primary office: Sign up to view
Phone: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

Biologs
Provider of genetic information management tool
Life Sciences TechnologyFrankfurt Am Main, Germany
Apurano Pharmaceuticals
Provider of smart bio-nanotechnology pharmaceutical products for multiple diseases
Life Sciences TechnologyWarngau, Germany
Steptics
Provider of composite prosthesis for amputees
Life Sciences TechnologyMunchen, Germany

About Magnosco

What does Magnosco do?

Magnosa develops a device for the diagnosis of cancer. develops patented devices for the early detection of early malignant melanoma, the so-called dermatofluoroscopy.

Where is Magnosco headquartered?

Magnosco is headquartered in Berlin, Germany.

When was Magnosco founded?

Magnosco was founded in 2013.

Which sector is Magnosco in?

Magnosco operates in Life Sciences Technology.

Who are Magnosco's competitors?

Companies similar to Magnosco include Biologs, Apurano Pharmaceuticals, and Steptics.